Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS or oligoblastic AML
Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are conditions where the bone marrow struggles to make healthy blood cells. For many people with higher-risk disease, a stem cell transplant from a healthy donor offers the best hope of long-term recovery. Before having a transplant, patients need treatment to clear away as many abnormal cells as possible. This phase 2 trial compares a newer treatment called Vyxeos against standard treatments, such as azacitidine or standard chemotherapy. Vyxeos combines two chemotherapy medicines inside tiny fat bubbles to help them reach cancer cells more effectively. Researchers want to find out whether Vyxeos helps patients stay well for longer, causes fewer side effects, and helps more people safely reach their planned transplant within six months. The study also measures quality of life and overall recovery.
At a glance
What is this study about?
Bone marrow is the spongy tissue inside your bones that makes blood cells. In conditions like higher-risk MDS and oligoblastic AML, the bone marrow produces abnormal cells that crowd out healthy ones. A stem cell transplant replaces these faulty cells with healthy ones from a donor. However, having a successful transplant usually requires intensive treatment beforehand to bring the disease under control.
Currently, doctors use standard treatments such as azacitidine or traditional chemotherapy to prepare patients. This trial is testing whether an alternative medicine called Vyxeos works better. Vyxeos delivers two standard chemotherapy drugs (daunorubicin and cytarabine) packaged together in tiny fat particles. This design aims to deliver the medicine directly into the bone marrow cells while reducing damage to healthy tissues.
Researchers want to see if patients receiving Vyxeos stay free of complications for longer compared to those getting standard care. They will also look closely at whether more patients are able to proceed smoothly to their planned stem cell transplant, how well the treatment clears disease from the bone marrow, and how patients feel during their care.
Key takeaways
- A phase 2 trial comparing a newer medicine called Vyxeos with standard treatments.
- Aimed at adults with newly diagnosed, higher-risk MDS or oligoblastic AML.
- Designed to help prepare patients for a donor stem cell transplant within six months.
- Researchers are measuring how well the treatment controls the disease and protects quality of life.
- Taking part is completely voluntary and does not replace your planned transplant pathway.
Who may be eligible?
This study is open to adults aged 18 and over who have recently been diagnosed with higher-risk MDS or oligoblastic AML. To take part, you must not have had treatment for this condition yet.
You must also be considered suitable for a stem cell transplant using donor cells, and your medical team must intend for you to have this transplant within the next six months.
People who have already received intensive treatment for their condition, or who are not well enough to undergo chemotherapy and a stem cell transplant, will not be able to join. Your hospital doctor can check your general fitness and test results to see if this trial is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with higher-risk MDS or oligoblastic AML.
- I have not yet started treatment for this condition.
- My doctors plan for me to have a stem cell transplant within the next six months.
- I am well enough to receive intensive hospital-based treatment.
What does participation involve?
If you take part, you will be assigned to receive either the study treatment (Vyxeos) or standard medical care. Both options involve receiving medicine into a vein (an intravenous infusion) at the hospital. Because these are intensive treatments, you may need to stay in hospital for parts of your care.
You will have regular blood tests, physical checks, and bone marrow biopsies (where a small sample of marrow is taken with a needle) to check how well the treatment is working. You will also be asked to complete short questionnaires about your symptoms, day-to-day energy, and overall quality of life. The treatment phase takes place over the weeks leading up to your stem cell transplant, which is planned within six months of starting. After your treatment and transplant, doctors will continue to follow your health and recovery through regular clinic check-ups up until late 2026.
Potential risks and benefits
Locations (2)
- —UnverifiedAustria
- —UnverifiedGermany
Common questions
What is a stem cell transplant?
It is a procedure where your faulty blood-forming cells are replaced with healthy stem cells from a donor, giving your bone marrow a fresh start to make healthy blood cells.
How is Vyxeos different from standard chemotherapy?
Vyxeos puts two proven chemotherapy medicines into microscopic fat bubbles. This helps keep the medicines in the body longer and directs them more straight into the bone marrow.
Will taking part delay my transplant?
No. The study is specifically designed for people planning a transplant within the next six months, and the goal is to help you reach that transplant safely.
Can I choose which treatment I get?
No. A computer usually decides which treatment you receive so that doctors can compare the two approaches fairly.
What happens if I decide to leave the trial?
You are free to leave the trial at any point. Your doctors will simply switch you to the best available standard treatment, and your standard of care will not suffer.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.